Clinical Trials Logo

Type II Diabetes clinical trials

View clinical trials related to Type II Diabetes.

Filter by:

NCT ID: NCT05176210 Recruiting - Type II Diabetes Clinical Trials

Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects

Start date: December 22, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I, double-blind, placebo-controlled, randomized, single- and multiple-ascending dose study to evaluate new study intervention, PS1. PS1 is a potential blood glucose control medication, which is developed by Pharmasaga Co. Ltd. planned for treating type II diabetes mellitus (T2DM). This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), food effect and potential efficacy of PS1 in subjects.

NCT ID: NCT05120219 Active, not recruiting - Type II Diabetes Clinical Trials

A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers

Start date: October 13, 2021
Phase: Phase 1
Study type: Interventional

According to the objective, the trial is constituted by two study groups: one is food effect assessment group, and another is multiple dose pharmacokinetic assessment group. The primary objective is to (1) assess the effect of a meal (light-fat) on the single-dose PK of SHR3824 and metformin administered in the HR20033 FDC tablet in healthy Chinese subjects; (2) to characterize the single-dose and steady-state PK of SHR3824 and metformin following administration of the HR20033 FDC tablet to healthy subjects in the fed state. The secondary objective is to assess in healthy Chinese subjects, the safety and tolerability of the SHR3824 and Metformin after single doses (administered in the fed and fasted states) and multiple doses (administered in the fed state) of the HR20033 FDC tablet.

NCT ID: NCT05108350 Not yet recruiting - Type II Diabetes Clinical Trials

A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects

Start date: November 9, 2021
Phase: Phase 1
Study type: Interventional

The trial is to assess the bioequivalence between HR20033 FDC tablet and co-administration of SHR3824 tablets and metformin XR tablets. The primary objective is to evaluate bioequivalence of SHR3824 and Metformin in healthy Chinese subjects in the fed state. The secondary objective is to evaluate the safety of HR20033 FDC tablet in healthy Chinese subjects.

NCT ID: NCT05074732 Recruiting - Obesity Clinical Trials

Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.

D-FOREST
Start date: December 1, 2019
Phase:
Study type: Observational

The DUNDRUM Forensic Redevelopment Evaluation study (D-FOREST study) is a multi-site comprehensive evaluation of a complete National Forensic Mental Health Service. The study will have a prospective, observational, longitudinal design which will permit the evaluation of benefit over time for individual patients, groups of patients and the evaluation of the benefit in terms of service based outcomes of the redevelopment of a complete National Forensic Mental Health Service e.g. effects on waiting list times, length of stay. The study will systematically evaluate multiple domains of recovery in a complete National Forensic Service, including patients' physical health, mental health, offending behaviours and social and occupational functioning.

NCT ID: NCT05028140 Not yet recruiting - Type II Diabetes Clinical Trials

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

PIEMONTE
Start date: March 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Piemonte association in the treatment of type 2 diabetes mellitus

NCT ID: NCT04893135 Completed - Type II Diabetes Clinical Trials

Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes

RANKL-GLYC
Start date: October 11, 2021
Phase: N/A
Study type: Interventional

The rapid normalization of hyperglycemia can cause a neuropathy called Diabetes Treatment-Induced Neuropathy (NITD). This phenomenon induces the presence of hyper vascularization and inflammation in contact with the nerve ends. In another register in patients living with diabetes, it has been observed the development of a rare and devastating complication for the joints called the so-called neuroarthropathy of Charcot (CN).

NCT ID: NCT04843592 Completed - Type II Diabetes Clinical Trials

SOKARY Mobile Application With Type II Diabetes

DM
Start date: August 30, 2019
Phase:
Study type: Observational

Android mobile application named (SOKARY)

NCT ID: NCT04768673 Completed - Type II Diabetes Clinical Trials

A Study to Investigate the PK and Safety of CKD-393

Start date: March 26, 2021
Phase: Phase 1
Study type: Interventional

A clinical trial to investigate the pharmacokinetics and safety after oral administration of CKD-393

NCT ID: NCT04715776 Enrolling by invitation - Type II Diabetes Clinical Trials

Supplementation of Brown Seaweed on Insulin Resistance of NAFLD Patients With Pre- or Type 2-Diabetes

Start date: December 10, 2018
Phase: N/A
Study type: Interventional

Investigators research team conducted a previous human clinical trial of brown algae and conducted liver and metabolic indicators of brown algae to improve nonalcoholic fatty liver disease, and found brown algae extract (LMF-HSFx, commodity In addition to reducing the liver function index, HbA1c in some patients with early stage diabetes or type 2 diabetes has an improved effect. In the mouse model of type 2 diabetes, comprehensive anti-hyperglycemia, anti-hyperlipidemia and hepatoprotective activity were studied using LMF-HSFx. Intake of LMF-HSFx reduced fasting blood glucose, increased adiponectin levels, reduced urine glucose, and improved hepatic glucose metabolism. LMF-HSFx can improve glucose and lipid metabolism in adipose tissue of diabetic mice, and inflammatory factors such as TNF-α and IL-6 can also be reduced. In this study,participants will be given Fuco-HiQ, and their effects on blood glucose and various metabolic indicators will be evaluated.

NCT ID: NCT04639492 Completed - Type-II Diabetes Clinical Trials

Postbiotic MBS and Metformin Combination in Patients With T2DM

Start date: November 2, 2020
Phase: N/A
Study type: Interventional

The primary objective is to evaluate the effect of MBS treatment in human subjects, and to validate its impact on intestinal flora and diabetes symptoms on diabetic patients undertaking metformin. The scientific data collected will be referenced for future product development.